The Trump administration declined an offer from Pfizer to buy more doses of its COVID-19 vaccine at the end of the summer, according to several reports.
The New York Times first reported Monday that Pfizer offered to sell the U.S. government more of its promising vaccine candidate, developed in partnership with the German company BioNTech. The U.S. agreed to buy 100 million doses of the Pfizer drug in July, but the vaccine takes two injections to work, meaning the contract is only enough for 50 million people. (At the time, there were several promising vaccine candidates, but none had shown widespread efficacy in late-stage, large-scale trials).
